Dependence on surgeon and clinic adoption
The system requires specialist training and clinical acceptance before procedures scale.
- Scope
- OPRA Implant System sales and S1/S2 procedure volumes
- Materiality
- high
Integrum
Integrum is a Swedish medical technology company focused on osseointegration systems that connect prosthetic limbs directly to the skeleton. Its core offering is the OPRA Implant System, supported by surgical procedures, implant components, and related devices used through a network of specialist clinics and Centers of Excellence, with the US as its main market and additional activity in Europe and other international markets.
| % | |
|---|---|
| OPRA Implant System | 55% Implant-based osseointegration system used to attach prosthetic limbs directly to bone. |
| Surgical procedures | 25% First- and second-stage procedures performed by specialist surgeons to implant and complete the system. |
| Axor II and related components | 15% Safety coupling and accessory components used with the implant system and prosthetics. |
| Clinical support and training | 5% Education, onboarding, and support services for clinics and partner hospitals. |
Integrum sells primarily to specialist hospitals, orthopedic surgeons, and rehabilitation-focused clinics that treat...
- Specialist hospitalsprimary
Buy the implant system and procedures for advanced amputee reconstruction and prosthetic attachment.
- Orthopedic surgeonsprimary
Adopt the OPRA system and perform S1/S2 procedures as part of their surgical practice.
- Rehabilitation centerssecondary
Support patient evaluation, recovery, and long-term functional follow-up.
- Centers of Excellenceprimary
Serve as referral and treatment hubs for complex osseointegration cases.
- Patients with limb losssecondary
End users of the system, reached through hospitals and specialist clinics.
Integrum is headquartered in Mölndal, Sweden, and operates through a Swedish parent company with a US subsidiary and...
- •Headquartered in Mölndal, Sweden
- •US is the largest disclosed revenue market
- •Rest of World includes DACH, Ukraine, and Israel
- •Commercial activity depends on local clinic adoption
- •Market access and reimbursement vary by country
Integrum’s strategy centers on expanding the commercial reach of the OPRA Implant System by concentrating on Centers of...
01
Concentrate on Centers of Excellenceshort-term
Specialist hubs improve procedure volume, referral quality, and clinical credibility.
02
Improve digital patient flowshort-term
Better intake and follow-up can shorten lead times and improve conversion to surgery.
03
Expand in priority international marketsmedium-term
Broader geographic reach reduces dependence on one market and supports growth.
04
Strengthen surgeon training and clinical supportmedium-term
Adoption depends on surgeon familiarity, procedure quality, and partner confidence.
Integrum’s business depends on surgeon adoption, reimbursement, and the pace at which clinics move from interest to...
Geographic concentration in the US
A large share of revenue comes from one market, making results sensitive to local demand and reimbursement.
- Scope
- US market revenue and procedure activity
- Materiality
- high
Regulatory and certification risk
Medical device commercialization depends on permits, certifications, and compliance.
- Scope
- Product approvals and market access
- Materiality
- high
Supplier and product quality risk
Specialized implants and components must meet strict quality standards to avoid disruption or recalls.
- Scope
- Implant system components and surgical kits
- Materiality
- high
Foreign exchange risk
The company reports in SEK but earns revenue in multiple currencies, creating translation and transaction effects.
- Scope
- US and international operations
- Materiality
- medium
Capitalized development expenditures
Affects intangible assets, operating expenses, and impairment risk
Revenue timing across staged procedures
Can create quarter-to-quarter volatility in reported sales
IFRS 16
IFRS 16 leases
Changes lease liabilities, depreciation, and interest expense
Foreign exchange translation
Can move equity and other comprehensive income
Impairment testing
Potential write-downs if expected cash flows weaken
: 11/08/2026